PharmiWeb.com - Global Pharma News & Resources
24-Jan-2019

Global Allergic Conjunctivitis API Manufacturers, Marketed and Phase III Drugs Landscape, 2019-2021: Route of Synthesis, Regulatory Milestones, & Forecasted Sales Estimates

Global Allergic Conjunctivitis API Manufacturers, Marketed and Phase III Drugs Landscape, 2019-2021: Route of Synthesis, Regulatory Milestones, & Forecasted Sales Estimates

PR Newswire

DUBLIN, Jan. 24, 2019

DUBLIN, Jan. 24, 2019 /PRNewswire/ --

The "Allergic Conjunctivitis - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Allergic Conjunctivitis - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2019" report provides comprehensive insights about marketed and Phase III products for Allergic Conjunctivitis . The report includes information of marketed products including their product description, patent details, forecasted sales till 2021 & API manufacturer details by country.

Global API Manufacturers of Marketed Products for Allergic Conjunctivitis

Coverage of API manufacturers for Allergic Conjunctivitis marketed products spanning across United States, Europe, China and India. The manufacturers' details include manufacturers' name along with their location.

Emerging Phase III products for Allergic Conjunctivitis

This report provides a comprehensive understanding of the emerging Phase III therapies for Allergic Conjunctivitis which can turn out to be future prospective competitors for the marketed products. It will also put light on the current market trends. Their forecasted global sales are also provided till 2021.

Scope

  • A review of the marketed products for Allergic Conjunctivitis including their description, route of synthesis, regulatory milestones, forecasted sales estimates till 2021 and API manufacturer details.
  • Patent information coverage of the marketed products including the patent number, holder, grant and patent expiry details
  • API manufacturers for the marketed products with location details
  • Emerging Phase III product profiles for Allergic Conjunctivitis including product description, developmental activities, licensors & collaborators and chemical information

Reasons to Buy

  • API intelligence for marketed drugs for the indication and gaining insights of API manufacturers
  • Evaluate the marketing status and patent details of products to exploit opportunities for generic drug development
  • Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to the indication
  • Establish a comprehensive understanding of the emerging Phase III products which can be future competitors in this space

Key Topics Covered:

1. Report Introduction

2. Allergic Conjunctivitis: Overview

  • Risk Factors
  • Causes
  • Symptoms
  • Pathophysiology
  • Prognosis
  • Diagnosis
  • Treatment

3. Comparative Analysis of Marketed and Emerging Products

4. Marketed Therapies

  • Product Description
  • Route of Synthesis
  • Mechanism of Action
  • Pharmacology
  • Pharmacodynamics
  • Pharmacokinetics
  • Adverse Reactions
  • Clinical Trials
  • Regulatory Milestones
  • Product Development Activities
  • Product Details
  • United States
  • Europe
  • Global Sales Assessment
  • Historical Global Sales
  • Forecasted Global Sales
  • Patent Details

5. Emerging Therapies (Phase III)

  • Product Description
  • Research and Development
  • Product Development Activities
  • Forecasted Global Sales

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/3tzfpq/global_allergic?w=5

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Laura Wood, Senior Manager
press@researchandmarkets.com  

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/global-allergic-conjunctivitis-api-manufacturers-marketed-and-phase-iii-drugs-landscape-2019-2021-route-of-synthesis-regulatory-milestones--forecasted-sales-estimates-300783608.html

SOURCE Research and Markets

Editor Details

Last Updated: 24-Jan-2019